MedTrace Logo

Clinical Results of Bisphosphonate and Denosumab Therapy Following Teriparatide Therapy for Japanese

NCT02166437 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2016-10-19

No results posted yet for this study

Summary

In this study, the investigators would like to analyze the bone mineral density (BMD) , bone turnover makers, and fracture prevention effects of bisphosphonate and denosumab randomly divided following daily teriparatide in Japanese patients under clinical practice. The participants are treated in the investigators hospital, who are under severe osteoporotic condition.

Conditions

Sponsors & Collaborators

  • Tomidahama Hospital

    lead OTHER

Principal Investigators

  • Rui Niimi, MD, PhD · Tomidahama Hospital

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2017-11-30
Completion
2018-11-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02166437 on ClinicalTrials.gov